Almirall: Announces a higher than expected milestone payment from AstraZeneca
Almirall: Announces a higher than expected milestone payment from AstraZeneca
- The company had built positive expectations
- The 2017 guidance looks secured
- Recommendation: Hold
Finally some good news for Almirall in a year marred with profit warnings and cancellations of some projects in Phase III. Our Hold recommendation and target price of €10.48 are unchanged.
Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Bankinter S.A. is a Spanish brokerage firm established in 1989. The company's line of business includes the provision of market research and trading services for Equity and Fixed Income products.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.